BioControl Becomes Latest Company To Report Disappointing Outcomes With VNS Therapy For Heart Failure
This article was originally published in Clinica
BioControl Medical has terminated the INOVATE HF trial of its CardioFit vagus nerve stimulator (VNS) for the treatment of heart failure, after a pre-specified interim analysis showed the trial had little chance of meeting its primary endpoint.
You may also be interested in...
The $250m deal adds A&E Medical’s sternal sutures, cable systems, and rigid fixation systems to Zimmer Biomet’s Dental, Spine & Craniomaxillofacial and Thoracic business.
The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.
The sale of BTG Specialty Pharmaceuticals to two affiliates of European specialty firm SERB leaves Boston Scientific with BTG’s interventional oncology and vascular products.